Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avinger, Inc. stock logo
AVGR
Avinger
$3.69
-2.6%
$3.41
$2.50
$18.00
$5.87M1.2646,810 shs3,255 shs
Femasys Inc. stock logo
FEMY
Femasys
$1.33
+4.7%
$1.60
$0.25
$4.75
$29.39M-3638,415 shs280,799 shs
Nephros, Inc. stock logo
NEPH
Nephros
$2.11
+1.0%
$2.57
$1.13
$4.04
$22.24M1.3119,306 shs1,242 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avinger, Inc. stock logo
AVGR
Avinger
-3.15%+1.93%+25.51%+32.73%-58.06%
Femasys Inc. stock logo
FEMY
Femasys
+4.72%+1.53%-19.88%+68.35%+53.05%
Nephros, Inc. stock logo
NEPH
Nephros
+0.96%+3.94%-10.97%-40.56%+49.65%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avinger, Inc. stock logo
AVGR
Avinger
1.9043 of 5 stars
3.55.00.00.00.00.80.6
Femasys Inc. stock logo
FEMY
Femasys
2.5372 of 5 stars
3.52.00.00.03.22.50.6
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avinger, Inc. stock logo
AVGR
Avinger
3.00
Buy$5.0035.50% Upside
Femasys Inc. stock logo
FEMY
Femasys
3.00
Buy$11.33752.13% Upside
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/A

Current Analyst Ratings

Latest FEMY, NEPH, and AVGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Femasys Inc. stock logo
FEMY
Femasys
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
4/1/2024
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $12.00
3/21/2024
Avinger, Inc. stock logo
AVGR
Avinger
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/21/2024
Femasys Inc. stock logo
FEMY
Femasys
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
3/21/2024
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/20/2024
Femasys Inc. stock logo
FEMY
Femasys
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.77N/AN/A($4.53) per share-0.81
Femasys Inc. stock logo
FEMY
Femasys
$1.07M27.47N/AN/A$0.85 per share1.56
Nephros, Inc. stock logo
NEPH
Nephros
$14.24M1.56N/AN/A$0.80 per share2.64

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)
Femasys Inc. stock logo
FEMY
Femasys
-$14.25M-$0.92N/AN/AN/A-1,329.10%-105.47%-80.50%5/9/2024 (Estimated)
Nephros, Inc. stock logo
NEPH
Nephros
-$1.58M-$0.15N/AN/A-11.06%-18.25%-14.29%5/8/2024 (Estimated)

Latest FEMY, NEPH, and AVGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Femasys Inc. stock logo
FEMY
Femasys
-$0.19-$0.19N/A-$0.19$0.30 million$0.21 million
3/20/2024Q4 2023
Avinger, Inc. stock logo
AVGR
Avinger
$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 million
3/7/2024Q4 2023
Nephros, Inc. stock logo
NEPH
Nephros
N/A-$0.06-$0.06-$0.06N/A$3.25 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
Nephros, Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avinger, Inc. stock logo
AVGR
Avinger
N/A
0.63
0.36
Femasys Inc. stock logo
FEMY
Femasys
0.24
7.59
7.37
Nephros, Inc. stock logo
NEPH
Nephros
N/A
3.98
2.81

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
Femasys Inc. stock logo
FEMY
Femasys
65.27%
Nephros, Inc. stock logo
NEPH
Nephros
41.10%

Insider Ownership

CompanyInsider Ownership
Avinger, Inc. stock logo
AVGR
Avinger
11.40%
Femasys Inc. stock logo
FEMY
Femasys
16.39%
Nephros, Inc. stock logo
NEPH
Nephros
4.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avinger, Inc. stock logo
AVGR
Avinger
681.59 million1.41 millionNot Optionable
Femasys Inc. stock logo
FEMY
Femasys
3222.10 million18.48 millionNot Optionable
Nephros, Inc. stock logo
NEPH
Nephros
3110.54 million10.11 millionNot Optionable

FEMY, NEPH, and AVGR Headlines

SourceHeadline
Nephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024Nephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
finance.yahoo.com - April 23 at 8:26 AM
Nephros, Inc. (NEPH) Interactive Stock Chart - Yahoo FinanceNephros, Inc. (NEPH) Interactive Stock Chart - Yahoo Finance
finance.yahoo.com - April 20 at 2:20 PM
Nephros, Inc.s (NASDAQ:NEPH) Profit OutlookNephros, Inc.'s (NASDAQ:NEPH) Profit Outlook
finance.yahoo.com - April 19 at 2:44 PM
Nephros (NASDAQ:NEPH)  Shares Down 0.5% Nephros (NASDAQ:NEPH) Shares Down 0.5%
americanbankingnews.com - April 16 at 1:52 AM
Nephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsNephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - March 11 at 11:49 PM
Nephros Full Year 2023 Earnings: Misses ExpectationsNephros Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 10 at 9:26 AM
Nephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized OperationsNephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized Operations
markets.businessinsider.com - March 9 at 7:27 PM
Nephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy RatingNephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy Rating
markets.businessinsider.com - March 9 at 12:36 AM
Nephros just upgraded at Benchmark, heres whyNephros just upgraded at Benchmark, here's why
realmoney.thestreet.com - March 8 at 4:31 PM
Nephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call TranscriptNephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 8 at 2:34 PM
NEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023NEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023
msn.com - March 7 at 10:44 PM
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsNephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - March 7 at 4:15 PM
Earnings Outlook For NephrosEarnings Outlook For Nephros
benzinga.com - March 6 at 4:41 PM
Nephros earnings: heres what to expectNephros earnings: here's what to expect
markets.businessinsider.com - March 6 at 4:41 PM
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial ResultsNephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - February 29 at 4:30 PM
Point-of-Use Filter Market Analysis With Top Key Players, Applications, And Trends During The Forecast PeriodPoint-of-Use Filter Market Analysis With Top Key Players, Applications, And Trends During The Forecast Period
opprairie.com - February 12 at 10:38 AM
What Is Nephros, Inc.s (NASDAQ:NEPH) Share Price Doing?What Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?
finance.yahoo.com - January 28 at 9:53 AM
Rezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerRezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
finanznachrichten.de - January 24 at 1:41 PM
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerRezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
finance.yahoo.com - January 24 at 8:40 AM
Nephros, Inc.s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price BounceNephros, Inc.'s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price Bounce
finance.yahoo.com - December 18 at 8:54 AM
Nephros Inc NEPHNephros Inc NEPH
morningstar.com - December 14 at 12:08 AM
Are Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?Are Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?
finance.yahoo.com - December 13 at 6:29 AM
Nephros CEO buys 18k shares of the company - filingNephros CEO buys 18k shares of the company - filing
msn.com - December 12 at 5:38 PM
Traeger heats up after attracting bull rating from B. RileyTraeger heats up after attracting bull rating from B. Riley
msn.com - December 12 at 12:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avinger logo

Avinger

NASDAQ:AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
Femasys logo

Femasys

NASDAQ:FEMY
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Nephros logo

Nephros

NASDAQ:NEPH
Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.